PL2061513T3 - Sposób leczenia pacjentów chorych na wirusowe zapalenie wątroby typu C - Google Patents

Sposób leczenia pacjentów chorych na wirusowe zapalenie wątroby typu C

Info

Publication number
PL2061513T3
PL2061513T3 PL08831728T PL08831728T PL2061513T3 PL 2061513 T3 PL2061513 T3 PL 2061513T3 PL 08831728 T PL08831728 T PL 08831728T PL 08831728 T PL08831728 T PL 08831728T PL 2061513 T3 PL2061513 T3 PL 2061513T3
Authority
PL
Poland
Prior art keywords
patients
treating hepatitis
hepatitis
relapsed
infection
Prior art date
Application number
PL08831728T
Other languages
English (en)
Inventor
Janice K Albrecht
Clifford A Brass
Robert Orville Ii Ralston
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2061513(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PL2061513T3 publication Critical patent/PL2061513T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
PL08831728T 2007-09-14 2008-09-11 Sposób leczenia pacjentów chorych na wirusowe zapalenie wątroby typu C PL2061513T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99375307P 2007-09-14 2007-09-14
US99876207P 2007-10-12 2007-10-12
US149407P 2007-10-30 2007-10-30
EP08831728A EP2061513B1 (en) 2007-09-14 2008-09-11 Method of treating hepatitis c patients
PCT/US2008/010626 WO2009038663A1 (en) 2007-09-14 2008-09-11 Method of treating hepatitis c patients

Publications (1)

Publication Number Publication Date
PL2061513T3 true PL2061513T3 (pl) 2011-12-30

Family

ID=40262964

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08831728T PL2061513T3 (pl) 2007-09-14 2008-09-11 Sposób leczenia pacjentów chorych na wirusowe zapalenie wątroby typu C

Country Status (17)

Country Link
US (1) US20100226885A1 (pl)
EP (2) EP2489369A1 (pl)
JP (1) JP2010539165A (pl)
CN (1) CN101883590A (pl)
AT (1) ATE519503T1 (pl)
AU (1) AU2008301981A1 (pl)
CA (1) CA2699280A1 (pl)
CY (1) CY1112116T1 (pl)
DK (1) DK2061513T3 (pl)
ES (1) ES2369321T3 (pl)
HR (1) HRP20110637T1 (pl)
MX (1) MX2010002909A (pl)
NZ (1) NZ583825A (pl)
PL (1) PL2061513T3 (pl)
PT (1) PT2061513E (pl)
SI (1) SI2061513T1 (pl)
WO (1) WO2009038663A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
EP2704576A4 (en) * 2011-05-04 2014-12-10 Merck Sharp & Dohme METHOD FOR THE PRODUCTION OF INHIBITORS OF HEPATITIS C VIRUS
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
BR112014010295A2 (pt) 2011-10-31 2017-04-18 Gilead Pharmassett Llc métodos e composições para o tratamento de vírus de hepatite c
JP5899327B2 (ja) * 2011-11-29 2016-04-06 ギリアド ファーマセット エルエルシー Ｃ型肝炎ウイルスを処置するための組成物および方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013116592A1 (en) 2012-02-01 2013-08-08 Kadmon Pharmaceuticals, Llc Once daily treatment of hepatitis c with ribavirin and taribavirin
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2000037110A2 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
CO5160259A1 (es) * 1999-03-02 2002-05-30 Schering Corp Interferon alfa pegilado en la terapia contra el hiv
DK1385870T3 (da) * 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
DE602005021760D1 (de) 2004-02-27 2010-07-22 Schering Corp Schwefelverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
WO2006016930A2 (en) * 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
MX2008010355A (es) * 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
JP2011522862A (ja) * 2008-06-10 2011-08-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法

Also Published As

Publication number Publication date
HRP20110637T1 (hr) 2011-10-31
PT2061513E (pt) 2011-10-17
CN101883590A (zh) 2010-11-10
NZ583825A (en) 2012-06-29
AU2008301981A1 (en) 2009-03-26
MX2010002909A (es) 2010-03-30
HK1129315A1 (en) 2009-11-27
ES2369321T3 (es) 2011-11-29
JP2010539165A (ja) 2010-12-16
EP2061513A1 (en) 2009-05-27
SI2061513T1 (sl) 2011-11-30
ATE519503T1 (de) 2011-08-15
DK2061513T3 (da) 2011-11-21
CY1112116T1 (el) 2015-11-04
WO2009038663A1 (en) 2009-03-26
EP2489369A1 (en) 2012-08-22
EP2061513B1 (en) 2011-08-10
US20100226885A1 (en) 2010-09-09
CA2699280A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
PL2061513T3 (pl) Sposób leczenia pacjentów chorych na wirusowe zapalenie wątroby typu C
PL2219642T3 (pl) Komponent sylibininy do leczenia zapalenia wątroby
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
IL177490A0 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
MY144318A (en) Methods of treating hiv infection.
SG150559A1 (en) Antineoplastic combinations of cci-779 and rituximab
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
PL1799231T3 (pl) Zastosowanie cyklodekstryny do leczenia i zapobiegania chorobom zapalnym oskrzeli
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
WO2009033183A3 (en) Compounds and methods for treatment of hcv and conditions associated with cd81 binding
UA88655C2 (ru) S-миртазапин для лечения прилива крови
PL383722A1 (pl) Sposoby i materiały z trans-klomifenem do leczenia bezpłodności u mężczyzn
IL187160A0 (en) Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
EP1827475A4 (en) METHOD FOR TREATING HIV INFECTION
GB2441094B (en) Methods for treatment and prevention of infection
MY166063A (en) Intravenous antiviral treatments
UA90477C2 (ru) Способ лечения гепатита с (варианты)
GB0509911D0 (en) Medical treatment aid for use in treating children
EP1879519A4 (en) IMPLANTABLE SLINGS FOR TREATING INCONTINENCE AND USE METHOD THEREFOR
IL187889A0 (en) Compositions and methods for preventing or treating hiv infection
UA39877U (uk) Спосіб ортопедичного лікування хворих з частковими дефектами зубних рядів та патологією серцево-судинної системи
UA32892U (ru) Способ лечения больных туберкулезом легких